Product

VemoHerb® deCox

Prevention and treatment of coccidiosis in poultry
An Innovative SAFE & NATURAL Solution

VemoHerb®  deCox’s proprietary blend of Artemisia spp. extract supports the prevention and treatment of coccidiosis hence reducing the economic impacts through enhanced feed conversion ratios and reduced mortality.

What is VemoHerb® deCox?

VemoHerb® deCox is formulated with a blend of herbs with a special emphasis on artemisinin, derived from Artemisia species for a natural control of coccidiosis. In contrast to many synthetic coccidiostats, this method does not develop drug-resistant Eimeria strains, which means that its effectiveness does not decrease with time. It mitigates gut inflammation, enhances recovery rates, and decreases mortality, making it a suitable option for poultry producers who are on constant lookout for better and safer solutions!

  • An alternative to synthetic products, which helps in the fight against coccidiosis and strengthens the immune system, resulting in healthier and more productive flocks; 
  • А cost-effective and risk-free solution to coccidiostats and vaccines; 
  • A phytogenic formula, which does not lead to and prevents the development of drug-resistant Eimeria strains.
  • Encourages recovery;
  • Reduces losses brought on by impacted growth and FCR;
  • Lowers mortality;
  • Diminishes oocyst shedding;
  • Reduces gut inflammation and speeds up healing;
  • Stimulates the immune response against numerous Eimeria sp.;
  • Prevents subsequent bacterial infections.
  • Resistance development: 

Overuse or misuse of anticoccidial drugs can result in drug-resistant strains of coccidia, making disease control more challenging and often requiring more expensive or alternative treatments.

  • Risk of secondary infections: 

Coccidiosis compromises the immune system, increasing their vulnerability to secondary infections. This not only complicates disease management but can also further impact flock health and productivity.

  • Rising treatment costs:

Managing coccidiosis comes with substantial costs, including the use of anticoccidial drugs, vaccines, and the labor required to treat infected flocks. These expenses can significantly impact a farmer’s overall profitability.  

VemoHerb® deCox can be used for:

  • prevention at the dosage of 200 g/t feed;
  • treatment at the dosage of 800 g/t feed.
Vemoherb Decox 05

Test groups: 

  1. Negative control – Chickens without challenge and treatment

  2. Positive control – Chickens were challenged at day 21 but untreated

  3. Diclazuril prevention – Chickens were challenged at day 21 and treated with 0.2 g/Kg of diclazuril (prevention dose) from day 1 to 42.

  4. Diclazuril treatment – Chickens were challenged at day 21 and treated with 0.2 g/Kg of diclazuril (prevention dose) from day 1 to 20 and treated with 0.8 g/Kg of diclazuril (treatment dose) from day 21 to 42.

  5. VemoHerb® deCox prevention – Chickens were challenged at day 21 and treated with 0.2 g/Kg of VemoHerb® deCox (prevention dose) from day 1 to 42.

  6. VemoHerb® deCox treatment – Chickens were challenged at day 21 and treated with 0.2 g/Kg of VemoHerb® deCox (prevention dose) from day 1 to 20 and treated with 0.8 g/Kg of VemoHerb® deCox (treatment dose) from day 21 to 42.

  7. Product B prevention – Chickens were challenged at day 21 and treated with 0.2 g/Kg of product B (prevention dose) from day 1 to 42.

  8. Product B treatment – Chickens were challenged at day 21 and treated with 0.2 g/Kg of product B (prevention dose) from day 1 to 20 and treated with 0.8 g/Kg of Product B (treatment dose) from day 21 to 42.

VemoHerb® deCox is based on the combination of herbal extracts, with the main ingredient of artemisinin from different Artemisia species.

Product B is based on concentrated plant steroidal saponins, extracted from Yucca and Trigonella species.

Vemoherb Decox 06

Among the challenged chickens, the lowest percentage of necrosis and epithelial tissue destruction was observed in the cecum and jejunum of chickens in the VemoHerb® deCox and diclazuril treatment groups.